{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:12:13Z","timestamp":1789135933281,"version":"build-2803163510"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The pharmacokinetics (PK) of immunosuppressive agents in living donor liver transplantation (LDLT) recipients are expected to differ from those in deceased donor liver transplantation (DDLT) recipients because of the smaller initial liver volume transplanted and pathophysiological changes during liver regeneration. Consequently, the hepatic metabolism, CYP enzyme activity, and glucuronidation may be reduced. The PK of tacrolimus (metabolized by CYP3A5) and mycophenolate (metabolized through glucuronidation) are expected to be affected early post-LDLT. However, the initial dosing recommendations for post-LDLT remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study aimed to recommend initial dosing approaches for tacrolimus and mycophenolate in LDLT recipients based on available PK data in humans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A PubMed search was conducted in March 2025 to identify studies investigating the PK data of immediate-release tacrolimus and mycophenolate in pediatric or adult LDLT recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      After screening, 8 and 8 articles on tacrolimus and mycophenolates, respectively, met the review criteria. The current literature suggests that LDLT recipients require lower tacrolimus doses than DDLT recipients, particularly in the early post-transplant period. In addition,\n                      <jats:italic toggle=\"yes\">CYP3A5<\/jats:italic>\n                      polymorphisms in both donors and recipients contribute to interindividual variability in tacrolimus exposure, further complicating tacrolimus management. Studies on mycophenolate use in LDLT recipients are limited, with insufficient evidence to support dose reduction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Reducing the initial tacrolimus dose in LDLT recipients by 30%\u201350% compared with that in DDLT recipients would be reasonable while maintaining the same initial dose of mycophenolate between LDLT and DDLT recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001477","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:00:27Z","timestamp":1780002027000},"page":"598-604","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Initial Dosing for Tacrolimus and Mycophenolate in Living Donor Liver Transplantation: A Systematic Critical Review"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6132-6869","authenticated-orcid":false,"given":"Kiara","family":"Bautista","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Michigan Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Park","sequence":"additional","affiliation":[{"name":"University of Michigan College, Department of Clinical Pharmacy, Michigan Medicine, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MOT.0000000000000610","article-title":"Living donor liver transplantation","volume":"24","author":"Goldaracena","year":"2019","journal-title":"Curr Opin Organ Transpl"},{"issue":"suppl 1","key":"R2-20260911","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S0168-8278(03)00009-6","article-title":"Living donor liver transplantation","volume":"38","author":"Broering","year":"2003","journal-title":"J Hepatol"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International liver transplantation society consensus statement on immunosuppression in liver transplant recipients","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantation"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/17425255.2016.1139575","article-title":"Pharmacokinetics of drugs in adult living donor liver transplant patients: regulatory factors and observations based on studies in animals and humans","volume":"12","author":"Li","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cld.2016.08.011","article-title":"Drug metabolism, drug interactions, and drug-induced liver injury in living donor liver transplant patients","volume":"21","author":"Ganesh","year":"2017","journal-title":"Clin Liver Dis"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1124\/dmd.104.002287","article-title":"Pharmacokinetics of tacrolimus and mycophenolic acid are altered, but recover at different times during hepatic regeneration in rats","volume":"33","author":"Tian","year":"2005","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/TP.0b013e3181642c95","article-title":"Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients","volume":"85","author":"Jain","year":"2008","journal-title":"Transplantation"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/jlts.2002.30885","article-title":"Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients","volume":"8","author":"Taber","year":"2002","journal-title":"Liver Transpl"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1053\/jlts.2002.31346","article-title":"Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients","volume":"8","author":"Trotter","year":"2002","journal-title":"Liver Transpl"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.3748\/wjg.15.3931","article-title":"Tacrolimus dosage requirements in living donor liver transplant recipients with small-for-size grafts","volume":"15","author":"Liu","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"55","DOI":"10.12659\/AOT.882219","article-title":"Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients","volume":"16","author":"Muraki","year":"2011","journal-title":"Ann Transpl"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/TP.0b013e318263700a","article-title":"Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation","volume":"94","author":"Ji","year":"2012","journal-title":"Transplantation"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"7647754","DOI":"10.1155\/2022\/7647754","article-title":"GRWR correlates with the metabolism of tacrolimus after pediatric living donor liver transplantation according to donor CYP3A5 polymorphism","volume":"2022","author":"Wan","year":"2022","journal-title":"Biomed Res Int"},{"key":"R17-20260911","first-page":"138","article-title":"Graft-to-Recipient weight ratio associated with tacrolimus metabolism following pediatric living donor liver transplantations","volume":"24","author":"Shoji","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0091270008315317","article-title":"Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients","volume":"48","author":"Jain","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/lt.21895","article-title":"Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients","volume":"15","author":"Shen","year":"2009","journal-title":"Liver Transpl"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:39Z","timestamp":1789135239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001477","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"2025-12-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}